摘要
目的:调查桂哌齐特致血液系统不良反应的临床特征以预防其发生。方法:以cinepazide、adverse reaction、leucopenia、agranulocytosis、thrombocytopenia、桂哌齐特、不良反应、白细胞、粒细胞和血小板为检索词,检索PubMed(1948-2010)、EMBASE(1966-2010)、中国生物医学文献数据库(CBM)(1978-2010)、中国期刊全文数据库(CNKI)(1979-2010)、中文科技期刊数据库(VIP)(1989-2010)、万方数据资源系统(1989-2010)和北京市药品不良反应监测网络(2005.01-2010.05),收集桂哌齐特致血液系统不良反应的文献和病例,对患者的一般情况、用药情况、不良反应类型和发生时间、临床表现、治疗措施和转归等资料进行回顾性分析。结果:获得桂哌齐特致血液系统不良反应的临床研究和不良反应报道共14篇,纳入16例患者,其中男性8例,女性8例,平均年龄(73.0±11.9)岁。原发病为脑梗死者9例,脑出血3例,外周动脉疾病3例、椎-基底动脉供血不足1例。桂哌齐特用药剂量为160、240、320、600和1200mg/d者分别为2、2、8、1和3例。用药后≤5、6～10、11～15和>15d发生不良反应者分别为7、3、1和5例。不良反应的首发症状多为发热。16例患者中有10例发生白细胞减少,4例发生粒细胞缺乏,1例发生血小板减少,1例同时发生白细胞和血小板减少。15例患者经停药及对症治疗,14例好转,1例死亡。1例患者未停药。结论:桂哌齐特易导致白细胞、粒细胞及血小板减少。临床应用桂哌齐特时应严密监测血液系统不良反应。
Objective：To investigate the clinical characteristics of hematological adverse reactions induced by cinepazide in order to prevent their development. Methods：Cinepazide,adverse reaction,leucopenia,agranulocytosis,and thrombocytopenia were selected as the search-words and PubMed（1948-2010）,EMBASE （1966-2010）,CBM（1978-2010）,CNKI（1979-2010）,VIP（1979-2010）,WANFANG DATA（1989-2010） as well as Adverse Drug Reaction Monitoring Network of Beijing were searched. The literatures and the case reports of hematological adverse reactions induced by cinepazide were collected. The data were analyzed retrospectively,including characteristics of patients,drug use,as well as types,onset time,clinical manifestations,treatment and prognosis to adverse reaction. Results：A total of 14 clinical research papers and the adverse drug reaction reports were selected ,16 patients were enrolled in this study. They comprised 8 men and 8 women with average age of （73.0±11.9） years. The primary diseases were cerebral infarction （9 cases）,cerebral hemorrhage （3 cases）,peripheral arterial embolism （3 cases） and vertebro-basilar arterial insufficiency （1 case）. Dosages of cinepazide were 160 mg/d （2 cases）,240 mg/d （2 cases）,320 mg/d （8 cases）,600mg/d （1 case） and 1 200 mg/d （3 cases）,respectively. The onset time to adverse reaction induced by cinepazide was within 5 days （7 cases）,6 to 10 days （3 cases）,11 to 15 days （1 case） and more than 15 days （5 cases） after treatment,respectively. The initial symptom of adverse reactions in most patients was fever. There were 10 patients with leucopenia,4 with agranulocytosis,1 with thrombocytopenia and 1 with both leucopenia and thrombocytopenia,in total of 16 patients. Fifteen patients received the drug discontinuation and symptomatic treatment,14 patients improved and 1 died. Another patient＇s drug was not withdrawn. Conclusion：Cinepazide is liable to decrease leckocyte,franulocyte,and platelet. Clinical cinepazide use should be followed by a careful hematological monitoring.
出处
《药物不良反应杂志》
2010年第4期251-254,共4页
Adverse Drug Reactions Journal
关键词
桂哌齐特
血液系统不良反应
cinepazide
hematological adverse reactions
